Acorda Therapeutics (ACOR) Misses Q3 EPS by 15c; Reiterates AMPYRA Net Sales Guidance

October 27, 2016 7:56 AM EDT

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Acorda Therapeutics (NASDAQ: ACOR) reported Q3 EPS of ($0.04), $0.15 worse than the analyst estimate of $0.11. Revenue for the quarter came in at $135.61 million versus the consensus estimate of $134.01 million.

The Company is reiterating 2016 AMPYRA net sales guidance of $475-$485 million.

For earnings history and earnings-related data on Acorda Therapeutics (ACOR) click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Earnings, Guidance

Related Entities

Earnings

Add Your Comment